 The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan Phase 1b portion of the study in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of relapsed small cell lung cancer patients treated with this combination therapy. The Phase 1b portion of the study is now complete. 